Regado Biosciences, Inc.: Series D $40M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

PDC Biotech, GmbH: Series A $5.5M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Dysmenorrhea

PDC Biotech (Austria) a preclinical-stage biopharmaceutical company focused upon women’s health preterm labor and primary dysmenorrhea, closed a $5.5M Series A financing. Participants include MIG Verwaltungs and Edmond de Rothschild Investment Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Probiodrug, AG: Series B $54M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Alzheimer's, X - Inflammation

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...